In conclusion, by supporting TGFβ/Smad3 signaling cAMP may enhance TGFβ/Smad3-induced EMT, generation of CSCs and breast cancer metastasis, thereby, deteriorate the outcome of breast cancer patients. This evidence concerns the gene SMAD3 and breast carcinoma.